A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury

NCT04335578 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

INDUSTRY

Sponsor class

Stopped Recruitment challenges

Conditions

Chronic Allograft Injury

Interventions

DRUG: Zampilimab
DRUG: Placebo

Sponsor

UCB Biopharma SRL